Beta-1 adrenergic receptor (ADRB1) (ADRB1)

The Beta-1 adrenergic receptor (ADRB1) is a G protein-coupled receptor predominantly located in cardiac tissue and the juxtaglomerular cells of the kidney. Upon stimulation by norepinephrine or epinephrine, the receptor activates Gs proteins, leading to an increase in intracellular cyclic AMP (cAMP) and subsequent activation of protein kinase A (UniProt P08588). This signaling cascade results in increased heart rate, enhanced myocardial contractility, and accelerated cardiac conduction, as well as the secretion of renin to regulate systemic blood pressure (StatPearls, 2023). ADRB1 is a critical therapeutic target in cardiovascular medicine; beta-1 selective antagonists like metoprolol and atenolol are standard treatments for hypertension, heart failure, and arrhythmias by reducing sympathetic overstimulation (PubMed, PMC6322519). In acute heart failure or cardiogenic shock, ADRB1 agonists such as dobutamine are employed to provide necessary inotropic support (IUPHAR/BPS Guide to Pharmacology). Understanding ADRB1 function is also vital for managing conditions like glaucoma, where non-selective beta-blockers reduce aqueous humor production. Genetic polymorphisms in the ADRB1 gene, such as the Arg389Gly variant, can significantly impact patient sensitivity to these medications, making it a focus for personalized cardiovascular therapy (NCBI Gene).

Other names

Beta-1 adrenoceptorADRB1RB1ARBeta-1 adrenoreceptor

Agonists bind to the receptor to activate Gs proteins, stimulating adenylyl cyclase and increasing intracellular cAMP levels to enhance cardiac output. Antagonists (beta-blockers) competitively inhibit the binding of endogenous catecholamines like epinephrine and norepinephrine, thereby reducing heart rate, contractility, and blood pressure.